Literature DB >> 27688570

Dengue: A Clinicohaematological Profile.

M Banerjee1, T Chatterjee2, G S Choudhary3, V Srinivas4, V K Kataria5.   

Abstract

BACKGROUND: Fifty cases of fever, clinically suspected to be dengue were studied.
METHODS: Complete clinical, haematological evaluation and IgM capture assay was done. RESULT: 54% of patients clinically suspected to have dengue were positive for IgM antibodies by enzyme-linked immunosorbent assay (ELISA). The commonest clinical feature was fever with rash (85%). Thrombocytopenia was seen in 19% of patients only. One patient died of dengue shock syndrome (DSS).
CONCLUSION: Out of the 27 cases of seropositive dengue there was one death due to dengue shock syndrome. Thrombocytopenia may not always be a feature of dengue.

Entities:  

Keywords:  Dengue haemorrhagic fever; Dengue shock syndrome; Thrombocytopenia

Year:  2011        PMID: 27688570      PMCID: PMC5035255          DOI: 10.1016/S0377-1237(08)80014-7

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  24 in total

Review 1.  Impact of dengue/dengue hemorrhagic fever on the developing world.

Authors:  D J Gubler; M Meltzer
Journal:  Adv Virus Res       Date:  1999       Impact factor: 9.937

Review 2.  Dengue: an update.

Authors:  María G Guzmán; Gustavo Kourí
Journal:  Lancet Infect Dis       Date:  2002-01       Impact factor: 25.071

3.  Influence of rheumatoid factor on the specificity of a rapid immunochromatographic test for diagnosing dengue infection.

Authors:  T Jelinek; J Wastlhuber; S Pröll; M Schattenkirchner; T Löscher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-07       Impact factor: 3.267

Review 4.  The global pandemic of dengue/dengue haemorrhagic fever: current status and prospects for the future.

Authors:  D J Gubler
Journal:  Ann Acad Med Singapore       Date:  1998-03       Impact factor: 2.473

5.  Antibody-enhanced binding of dengue-2 virus to human platelets.

Authors:  S Wang; R He; J Patarapotikul; B L Innis; R Anderson
Journal:  Virology       Date:  1995-10-20       Impact factor: 3.616

6.  Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants.

Authors:  S C Kliks; S Nimmanitya; A Nisalak; D S Burke
Journal:  Am J Trop Med Hyg       Date:  1988-03       Impact factor: 2.345

7.  Tumor necrosis factor alpha levels in plasma and whole-blood culture in dengue-infected patients: relationship between virus detection and pre-existing specific antibodies.

Authors:  D Hober; T L Nguyen; L Shen; D Q Ha; V T Huong; S Benyoucef; T H Nguyen; T M Bui; H K Loan; B L Le; A Bouzidi; D De Groote; M T Drouet; V Deubel; P Wattré
Journal:  J Med Virol       Date:  1998-03       Impact factor: 2.327

8.  Fatal dengue hemorrhagic fever in Cuba, 1997.

Authors:  M G Guzmán; M Alvarez; R Rodríguez; D Rosario; S Vázquez; L Vald s; M V Cabrera; G Kourí
Journal:  Int J Infect Dis       Date:  1999       Impact factor: 3.623

9.  Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection.

Authors:  E Chungue; L Poli; C Roche; P Gestas; P Glaziou; L J Markoff
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

Review 10.  Dengue: the risk to developed and developing countries.

Authors:  T P Monath
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

View more
  2 in total

1.  Clinicohematological profile and platelet trends in children with dengue during 2010 epidemic in north India.

Authors:  Hema Mittal; M M A Faridi; Shilpa Khanna Arora; Rahul Patil
Journal:  Indian J Pediatr       Date:  2011-10-29       Impact factor: 5.319

2.  Correlation of Clinicohaematological Parameters in Paediatric Dengue: A Retrospective Study.

Authors:  Ramakrishna Pai Jakribettu; Rekha Boloor; Andrew Thaliath; Sharanya Yesudasan George; Thomas George; Manoj Ponadka Rai; Umran Rafique Sheikh; Kadke Shreedhara Avabratha; Manjeshwar Shrinath Baliga
Journal:  J Trop Med       Date:  2015-12-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.